Growth was studied in 89 children with atopic eczema aged 1-16 years. Nine (10%) had a standing height below the 3rd centile. Both boys and girls had signiflcantly reduced sitting height but normal subischial leg length, and both sexes had significantly delayed skeletal maturity scores. Impaired growth was particularly associated with widespread eczema, but also with the presence of asthma and the potency of topical corticosteroid. Six of the 15 patients with a corrected height centile below the 10th centile had been receiving potent (British National Formulary category I or II) topical corticosteroids. This study suggests that impaired linear growth is a feature of atopic eczema. While the causes ofthe growth impairment are unclear, there is a need for caution in the use of potent topical corticosteroids in children.
Introduction
Short stature is sometimes seen in children with atopic eczema, but it has never been systematically studied, and it is not mentioned in the standard textbook on atopic eczema 1• Short stature could simply be a feature of asthma", which commonly coexists with eczema, or due to the use of topical corticosteroids. It was believed that 'active allergy' might cause growth failure, though the published data do not allow one to distinguish between the effects of 'allergy' and those of untreated asthma", Defective gastrointestinal handling of certain proteins may playa part in the pathogenesis ofatopic eczema", and partial villous atrophy was found among an atypical group of children with eczema", so malabsorption could contribute to growth failure. Inappropriate dietary restrictions, which may be seen in some children with eczema, can certainly impair growth". Children with severe eczema often sleep badly, and this might interfere with growth hormone release, We therefore decided to study the growth of a group of children with atopic eczema.
Patients and methods
Patients with atopic eczema attending the Department of Child Health at Booth Hall Children's Hospital were studied. The patients came from the north west of England, and were referred by paediatricians or dermatologists because of the severity or intractable nature of the disease. None was referred because of short stature. Information about growth prior to referral was not available. Only children who had had chronic atopic eczema for at least one year, who had at least 5% of the skin surface area affected, and who were regularly attending the Department, were included in this study. Patients with a shorter history or with minor lesions were not studied. All measurements of growth were made by a single observer (FK). Infants unable to stand unsupported were not studied. The series comprised 55 boys (aged 1.30-16.95 years, mean age 5.35 years) and 34 girls (aged 1.66-10.85 years, mean age 5.20 years). There were 69 patients aged between 2 and 9 years, the age group for which standards are available for children's height allowing for the height of parents'. The parents of these 69 patients were measured.
Height was measured with a Harpenden stadiometer. The child was stretched to maximum height by gentle pressure under the mastoid process. Sitting height (SH) was measured on a Harpenden Sitting Height table. Sub ischial leg length (SLL) was calculated as height minus sitting height. Weight was recorded on the same pair of scales. Triceps and subscapular skinfold thickness were recorded with a Holtain Tanner-Whitehouse skinfold calliper. The head circumference (HC) was measured using a steel tape. Skeletal maturation was assessed by a single observer (FK) with the TW2 method", using the radius, ulna, and short bones (metacarpals and phalanges) onlythe TW2 RUS score.
All the measurements, except weight, triceps and subscapular skinfold thickness, were expressed in standard deviation scores (s.d, scores). The values were calculated for the sexes separately, and comparisons with the normal standards made using the t test.
A single observer (TJD) assessed the severity of the eczema on a scale from 1 to 3 (1= mild, 2 = moderate, 3 = severe). The extent of the eczema was arbitrarily assessed by the surface area of skin affected on a scale from 1 to 3 (1=less than 10% affected, 2=10-50%, 3 = over 50%). The use of topical corticosteroids was graded as in the British National Formulary (BNF)9, but in reverse order, as follows: O=none, l=mild (BNF categoryIV), 2= moderately potent (BNF category III), 3=potent (BNF category II), 4 = very potent (BNF category I). Where more than one preparation was used, the most potent preparation was scored. The presence of asthma was crudely scored as: 0= none, l=mild asthma, 2=asthma requiring inhaled corticosteroids or admission to hospital. The use of inhaled corticosteroids was scored as 0 = none, 1=used. The use of an elimination diet was scored as 0= none, I:=; used. All these scores were applied to the patient's overall condition over the preceding two years.
Results
Nine (10%) of the 89 patients had a standing height below the third centile; 7 were boys, Six patients were more than -2 s.d, below the mean, and 3 were more than -2.5 s.d, below the mean. For both sexes the mean height was less than the average population mean ( Table 1 ). The overall distribution of height 0141·0768/87/ 010009·04/$02.00/0 <:11987 The Royal Society of Medicine -
related to normal centiles was not statistically significantly different for either boys or girls (see Table 1 and Figure 1 ). Both boys and girls had statistically significantly reduced 8H (t=3.85, P<O.OOl for girls; t=3,49, P<O.OOl for boys). The mean 8LL was not significantly different from the normal standards'P. These results demonstrated a disproportionately shorter SH compared to 8LL (Figure 2) . The difference between 8LL and SH had a mean value of 0.55 s.d. scores for the boys and 0.88 s.d. scores for the girls. According to Tanner and Whitehouse!!, the normal limits for SLL-SH are ±2 s.d, in boys aged 6-13 years and in girls aged 6-11 years; they are slightly larger (up to ±2.5 s.d.) in younger and older children. The normal upper limit of 8LL-8H was exceeded in 5 patients. In 33/54 boys and 22/32 girls the difference between 8LLand SH was positive, indicating a relatively larger reduction in 8H (Figure 2 ).
The centiledistributions for weight and skinfold thickness were not significantly different from those of the normal population (see Table 2 ). Thirty-two (58%) patients were below the 50th centile for weight, When the TW2 RUS skeletal maturity scores were plotted against chronological age, both boys and girls were found to be low on the centiles. Skeletal maturity expressed as s.d. scores was more delayed in the girls (t =2.65, P< 0.001) than in the boys (t =1.86, P < 0.05)(seeFigure 1 and Table 1 ).
The 69 pairs of parents had a slightly greater mean mid-parental height (168.8 em) than that reported for the normal British population (166.9 em) 7 • Of the 69 pairs of parents, 44 had a mid-parental height over 166.9 em. The 69 patients for whom the mid-parental height was available were subdivided into three groups according to the corrected height centile. Group A comprised those below the 10th centile, Group B between the 10th and 90th centiles, and Group C above the 90th centile (Table 3 ).There was a small but not statistically significant excess of boys over girls with a corrected height centile below the 10th centile. For each group, the scores of severity, extent, topical corticosteroid use, coexisting asthma, inhaled corticosteroid use, and use of elimination diet were averaged (Table 4 ). There were consistent trends of increasing disease extent, corticosteroid strength and asthma score with decreasing height centile. Two of the 15 patients aged 2-9 with a corrected height centile below the 10th centile had only a small surface area affected (less than 10%). Four of the 15 had not received any topical corticosteroids (one of these 4 had received weekly ACTH injections for over a year), and 6 of the 15 had never had asthma. However, 6 of the 15 patients had been regularly receiving potent (BNF category I or II) topical corticosteroids during the previous two years.
Discussion
Nine (10%) of 89 patients with atopic eczema in this cross-sectional study had a height below the 3rd centiIe. Of the 69 patients where study could include the mid-parental height, 15 (22%) had a corrected height centile below the 10th centile but only 6 (9%) had a corrected height centile above the 90th centile. The patients came from a very large area, and it was not possible to study control subjects from the same area. Our results were compared with national standards because there are none available for children living in Manchester or the north west of England. This does not invalidate the results, which for height are mainly based on centiIes corrected for midparental height. Further evidence of impaired linear growth comes from the observed disproportion between the SLL and SH. The normal skinfold thickness and weight are against malnutrition being a cause of impaired growth. The increased HC is unexplained. The delayed bone age is probably an associated feature of growth impairment, since the children with growth delay appeared to have a bone age retardation to a similar degree. However, this association cannot be accurately assessed without a longitudinal study.
The patients in this series are a selected group, with a bias towards severe, chronic or difficult cases, as in any hospital-based study. Nevertheless, if atopic eczema is associated with short stature, it would be found in such a series. The system for scoring severity and extent was crude and arbitrary. However, no clinical scoring system for the assessment of eczema is entirely satisfactory. The topical corticosteroid score suffers from the drawback that it takes into account only the potency of the preparation and not the quantity.
This study confirms the clinical impression that some children with atopic eczema are shorter than usual, and a few are very short. There were consistent trends of increasing disease extent, increasing corticosteroid strength and increasing asthma score with decreasing height centiIe. The data do not permit the exclusion of any of these three factors, though extensive disease was the single most consistent feature in those with growth impairment. It is notable that 6 of the 15 patients whose corrected height centile was below the 10th were regularly receiving potent (BNF category I or II) topical corticosteroids. The prolonged use of potent corticosteroids cannot be excluded as a cause of growth impairment in these 6 cases. If there is a causal relationship between exogenous corticosteroids and impaired growth in these patients, this would imply a selective impairment of spinal growth as the SLL was normal. The association of impaired growth and asthma is well recognized though its cause is unknown2.13.14. However, asthma cannot be the explanation for impaired growth in most cases, and is probably only indirectly associated as a feature of severe atopic disease. This is a cross-sectional study, and it is possible that what has been observed in some patients is a temporary growth delay (cause unknown) which may catch up later. The only way to resolve this is with a longitudinal study. Meanwhile, caution is needed in the use of potent topical corticosteroids for prolonged periods in children.
